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Background
To address the challenging goal of eliciting broadly neu-
tralizing antibodies (NAbs) to HIV, several immunization
strategies have been employed so far with little success.
We are interested in identifying immunization strategies
that will aid in more robust generation of NAbs both in
titer and sustainability. This study investigates the rela-
tionship between the frequencies of anti-HIV-1 Env B cells
generated during DNA-prime protein-boost immuniza-
tion with the titer of anti-Env antibodies, using three dif-
ferent Env immunogens.
Methods
Rhesus macaques were immunized with either soluble
trimeric wild type gp140 (wt-gp140), or monomeric
gp120 (m-gp120), or CD4-binding site mutant (D368R)
gp140 (D368R-gp140). Throughout immunization, the
frequency of HIV Env-specific B cells was evaluated by
multicolor flow cytometry, anti-Env antibody titers by
ELISA, and neutralization activity assayed using TZM-bl
assay.
Results
The frequency of HIV Env specific plasmablast subset
(CD3- CD20+ CD27high CD38 high) and titers of anti-
Env antibodies increased as a result of protein boost in
comparison with DNA prime in all immunized animals.
The average frequency of Env specific B cells after protein
immunization was 0.72% (0.47–0.99%) for the wt-
gp140, 0.44% (0.35–0.52%) for the gp120, and 0.35%
(0.13–0.56%) for the D368R gp140 immunized animals.
However, no significant correlations can be drawn
between the titer of Env specific antibodies and frequency
of Env specific B cells in any group. The wt-gp140 was a
more effective immunogen than m-gp120 in eliciting
weak cross-NAbs. Interestingly, the wt-gp140 was also
more effective in eliciting cross-NAbs than the
D368Rgp140; potentially suggesting that the develop-
ment of cross-NAbs by wt-gp140 depends on the struc-
tural integrity of the CD4-binding site.
Conclusion
Protein boosting is required for the development of high
frequencies of anti-HIV Env antibodies, and ability of
trimeric gp140 to elicit cross-NAbs will depend on the
structural integrity of the CD4-binding site.
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